CC BY
21
Abstracts. PHYTOPHARM 2017
flower petal (CTAF) on modulating gene expressions of pro-inflammatory mediators (myeloperoxidase/MPO, microsomal prostaglandin E synthase type 2/mPGES2, cyclooxygenase-1/COX-2, and inducible nitric oxyde syntase/iNOS) and their signaling pathways of mitogen-activated protein kinase (MAPK) and phosphoinositide 3-kinase (PI3K) in carragenan-induced rat paw edema in vivo. CTAF was extracted using solvent mixture of MeOH/acetone/H2O, followed by concentration, freeze drying, and quantification. CTAF was prepared on various doses (100-250, and 500 mg/kg bw) and given orally to Sprague-Dawley rats for 7 days. In vivo edema model was performed by injecting carrageenan into rat paw. The increasing of paw volume was measured after injection (1-5 hours), and the edema paw was
further collected to determine the action of CTAF on attenuating gene expression by quantitative Real Time-PCR. Our results demonstrated that rat paw volume increased until 3rd hours and decreased up to 27% at 5th hours after carragenan injection (p < 0.05). CTAF at 100 mg/kg bw showed similar inhibitory effect on reducing rat edema with ibuprofen standard (15 mg/kg bw). CTAF significantly reduced the gene expression of pro-inflammatory mediators, including MPO, mPGES2, COX-2, and iNOS. This gene inhibition was found to be mediated by MAPK and PI3K signaling pathways. Interestingly, CTAF efficacy is similar to NSAID drug of ibuprofen. Therefore, CTAF may offer a potential natural anti-inflammatory candidate from plants for management of inflammation-related diseases.
WOUND HEALING ACTIVITY OF PHLOMIS VISCOSA
© Ludmila Yarmolinsky1, Arie Budovsky2, Shimon Ben-Shabat3, Leonid Yarmolinsky4
1 Eastern R&D Center, Kiryat Arba, Israel;
2 Technological Center, Biotechnology Unit, Beer Sheva, Israel;
3 Department of Biochemistry and Pharmacology, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel;
4 Arnie Miller Lab, Beer-Sheva, Israel
Pro-wound healing properties of the ethanol extract from Phlomis viscosa Poiret from the Judea region (Israel) were reported on the basis of using both in vivo and in vitro models [1]. Preparation of cream formulation containing of P. viscosa extract was performed. Aim of the present study was to identify bioactive compounds including volatile terpenes.
Different parts of the examined plant (leaves, stems, flowers) were investigated by us using GS-MS, a Varian CP 3800 GS-MS analytical system. In addition, the analytical library (NIST standard reference database) was applied. The majority of compounds were present in leaves in accordance with the observation that the best pro-wound healing properties belonged to the ethanol extract prepared from P. viscosa leaves [1]. The following compounds were identified in the leaves: Isovaleraldehyde, 2,4-hexadienal, 2-hexenal, alpha-terpinene, 1-octen-3-ol, and himachala-2,4-diene.
We purified the active pro-wound healing compounds from this plant as described previously [2]. By using the Micro HPLC-ESI/MS and Orbitrap-based mass spectrometry and comparison with selected standards,
we confirmed the presence of diosmin in the active fraction of the extract.
Although the medicinal properties and constituents of the majority of species of the genus Phlomis are well known [3], those of P. viscosa were not investigated in depth so far. Thus, identification of additional pro-wound healing compounds is the major priority of our future research. In conclusion, the extract of P. viscosa is a rich source of new pro-wound healing compounds with potential of serving as a starting point for developing new therapeutic agents.
References:
1. Budovsky A, Shteinberg A, Maor H, Duman O, Yanai H, Wolfson M, Fraifeld VE. 2014. Rejuvenation Res. 17(2):134-139.
2. Yarmolinsky L, Huleihel M, Zaccai M, Ben-Shabat S. 2012. Fitoterapia. 83:362-367.
3. Amor ALB, Boubaker J, Sgaier MB, Skandrani I, Bhouri W, Neffati A, Kilani S, Bouhlel I, Ghedira K, Chekir-Ghedira L. 2009. J Ethnopharmacol. 125: 183-202.
Obzory po kliniceskoj farmacologii i lekarstvennoj terapii [Reviews of clinical pharmacology and drug therapy] vol. 15/2017/suppLement 1
1 79
